🚀 VC round data is live in beta, check it out!
Bioage Labs Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bioage Labs and similar public comparables like AprilBio, MannKind, Nika Pharmaceuticals, Solid Biosciences and more.
Bioage Labs Overview
About Bioage Labs
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
Founded
2015
HQ
Employees
64
Website
Sectors
Financials (LTM)
EV
$514M
Bioage Labs Financials
Bioage Labs reported last 12-month revenue of $8M and negative EBITDA of ($101M).
In the same LTM period, Bioage Labs generated $8M in gross profit, ($101M) in EBITDA losses, and had net loss of ($89M).
Revenue (LTM)
Bioage Labs P&L
In the most recent fiscal year, Bioage Labs reported revenue of $9M and EBITDA of ($80M).
Bioage Labs expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $8M | XXX | $9M | XXX | XXX | XXX |
| Gross Profit | $8M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($101M) | XXX | ($80M) | XXX | XXX | XXX |
| EBITDA Margin | (1301%) | XXX | (886%) | XXX | XXX | XXX |
| EBIT Margin | (1300%) | XXX | (1031%) | XXX | XXX | XXX |
| Net Profit | ($89M) | XXX | ($81M) | XXX | XXX | XXX |
| Net Margin | (1145%) | XXX | (896%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bioage Labs Stock Performance
Bioage Labs has current market cap of $790M, and enterprise value of $514M.
Market Cap Evolution
Bioage Labs' stock price is $17.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $514M | $790M | -1.4% | XXX | XXX | XXX | $-1.82 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioage Labs Valuation Multiples
Bioage Labs trades at 66.1x EV/Revenue multiple, and (5.1x) EV/EBITDA.
EV / Revenue (LTM)
Bioage Labs Financial Valuation Multiples
As of April 10, 2026, Bioage Labs has market cap of $790M and EV of $514M.
Equity research analysts estimate Bioage Labs' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bioage Labs has a P/E ratio of (8.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $790M | XXX | $790M | XXX | XXX | XXX |
| EV (current) | $514M | XXX | $514M | XXX | XXX | XXX |
| EV/Revenue | 66.1x | XXX | 57.1x | XXX | XXX | XXX |
| EV/EBITDA | (5.1x) | XXX | (6.4x) | XXX | XXX | XXX |
| EV/EBIT | (5.1x) | XXX | (5.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 66.1x | XXX | — | XXX | XXX | XXX |
| P/E | (8.9x) | XXX | (9.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (6.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bioage Labs Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bioage Labs Margins & Growth Rates
Bioage Labs' revenue in the last 12 month grew by 10%.
Bioage Labs' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.6M for the same period.
Bioage Labs' rule of 40 is (2772%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bioage Labs' rule of X is (2846%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Bioage Labs Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | (50%) | XXX | XXX | XXX |
| EBITDA Margin | (1301%) | XXX | (886%) | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 55% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (2772%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (2846%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.6M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 363% | XXX | 310% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1031% | XXX | 822% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1131% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Bioage Labs Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| AprilBio | XXX | XXX | XXX | XXX | XXX | XXX |
| MannKind | XXX | XXX | XXX | XXX | XXX | XXX |
| Nika Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Solid Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Kura Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bioage Labs M&A Activity
Bioage Labs acquired XXX companies to date.
Last acquisition by Bioage Labs was on XXXXXXXX, XXXXX. Bioage Labs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Bioage Labs
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioage Labs Investment Activity
Bioage Labs invested in XXX companies to date.
Bioage Labs made its latest investment on XXXXXXXX, XXXXX. Bioage Labs invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Bioage Labs
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bioage Labs
| When was Bioage Labs founded? | Bioage Labs was founded in 2015. |
| Where is Bioage Labs headquartered? | Bioage Labs is headquartered in United States. |
| How many employees does Bioage Labs have? | As of today, Bioage Labs has over 64 employees. |
| Who is the CEO of Bioage Labs? | Bioage Labs' CEO is Kristen Fortney. |
| Is Bioage Labs publicly listed? | Yes, Bioage Labs is a public company listed on Nasdaq. |
| What is the stock symbol of Bioage Labs? | Bioage Labs trades under BIOA ticker. |
| When did Bioage Labs go public? | Bioage Labs went public in 2024. |
| Who are competitors of Bioage Labs? | Bioage Labs main competitors are AprilBio, MannKind, Nika Pharmaceuticals, Solid Biosciences. |
| What is the current market cap of Bioage Labs? | Bioage Labs' current market cap is $790M. |
| What is the current revenue of Bioage Labs? | Bioage Labs' last 12 months revenue is $8M. |
| What is the current revenue growth of Bioage Labs? | Bioage Labs revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Bioage Labs? | Current revenue multiple of Bioage Labs is 66.1x. |
| Is Bioage Labs profitable? | No, Bioage Labs is not profitable. |
| What is the current EBITDA of Bioage Labs? | Bioage Labs has negative EBITDA and is not profitable. |
| What is Bioage Labs' EBITDA margin? | Bioage Labs' last 12 months EBITDA margin is (1301%). |
| What is the current EV/EBITDA multiple of Bioage Labs? | Current EBITDA multiple of Bioage Labs is (5.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.